Effects of High and Low Doses of Metformin, Fenofibrate and Simvastatin, Administered Together and in Sequence With Lifestyle Intervention on Lipid Profile, Glucose Metabolism, Low-grade Inflammation and Hemostasis in Patient's Blood Plasma in Type 2 Diabetic Patients With Serious Mixed Dyslipidemia.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Fenofibrate; Metformin; Simvastatin
- Indications Hyperlipidaemia; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms MSF
Most Recent Events
- 09 Jul 2012 Biomarkers information updated
- 07 Jul 2012 Planned end date changed from 1 Jul 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 28 Mar 2011 Status changed from not yet recruiting to active, no longer recruiting.